Quantcast
Connect with us

How ‘vaccine nationalism’ could block vulnerable populations’ access to COVID-19 vaccines

Published

on

Doctor holding vaccine. (AFP)

Hundreds of COVID-19 vaccine candidates are currently being developed. The way emerging vaccines will be distributed to those who need them is not yet clear. The United States has now twice indicated that it would like to secure priority access to doses of COVID-19 vaccine. Other countries, including India and Russia, have taken similar stances. This prioritization of domestic markets has become known as vaccine nationalism.

ADVERTISEMENT

As a researcher at Saint Louis University’s Center for Health Law Studies, I have been following the COVID-19 vaccine race. Vaccine nationalism is harmful for equitable access to vaccines – and, paradoxically, I’ve concluded it is detrimental even for the U.S. itself.

Vaccine nationalism during COVID-19

Vaccine nationalism occurs when a country manages to secure doses of vaccine for its own citizens or residents before they are made available in other countries. This is done through pre-purchase agreements between a government and a vaccine manufacturer.

In March, the White House met with representatives from CureVac, a German biotech company developing a COVID-19 vaccine. The U.S. government is reported to have inquired about the possibility of securing exclusive rights over the vaccine. This prompted the German government to comment that “Germany is not for sale.” Angela Merkel’s chief of staff promptly stated that a vaccine developed in Germany had to be made available in “Germany and the world.”

On June 15, the German government announced it would be investing 300 million euros (nearly US$340 million) in CureVac for a 23% stake in the company.

In April, the CEO of Sanofi, a French company whose COVID-19 vaccine work has received partial funding from the U.S Biomedical Advanced Research and Development Authority, announced that the U.S. had the “right to the largest pre-order” of vaccine.

ADVERTISEMENT

Following public outcry and pressure from the French government, Sanofi altered its stance and said that it would not negotiate priority rights with any country.

In India, the privately held Serum Institute is developing one of the leading COVID-19 vaccine candidates. The Serum Institute signaled that, if development of the vaccine succeeds, most of the initial batches of vaccine will be distributed within India.

At the same time, India, alongside the U.S. and Russia, chose not to join the Access to COVID-19 Tools Accelerator, which was launched by the World Health Organization to promote collaboration among countries in the development and distribution of COVID-19 vaccines and treatments.

ADVERTISEMENT

Vaccine nationalism is not new

Vaccine nationalism is not new. During the early stages of the 2009 H1N1 flu pandemic, some of the wealthiest countries entered into pre-purchase agreements with several pharmaceutical companies working on H1N1 vaccines.
At that time, it was estimated that, in the best-case scenario, the maximum number of vaccine doses that could be produced globally was 2 billion. The U.S. alone negotiated and obtained the right to buy 600,000 doses. All the countries that negotiated pre-purchase orders were developed economies.

Only when the 2009 pandemic began to unwind and demand for a vaccine dropped did developed countries offer to donate vaccine doses to poorer economies.

ADVERTISEMENT

The problems posed by nationalism

The most immediate effect of vaccine nationalism is that it further disadvantages countries with fewer resources and bargaining power. It deprives populations in the Global South from timely access to vital public health goods. Taken to its extreme, it allocates vaccines to moderately at-risk populations in wealthy countries over populations at higher risk in developing economies.

Vaccine nationalism also runs against the fundamental principles of vaccine development and global public health. Most vaccine development projects involve several parties from multiple countries.

With modern vaccines, there are very few instances in which a single country can claim to be the sole developer of a vaccine. And even if that were possible, global public health is borderless. As COVID-19 is illustrating, pathogens can travel the globe. Public health responses to outbreaks, which include the deployment of vaccines, have to acknowledge that reality.

ADVERTISEMENT

How nationalism can backfire in the US

The U.S. in notorious for its high drug prices. Does the U.S. government deserve to obtain exclusive rights for a vaccine that may be priced too high? Such a price may mean that fewer U.S. citizens and residents – especially those who are uninsured or underinsured – would have access to the vaccine. This phenomenon is a form of what economists call deadweight loss, as populations in need of a welfare-enhancing product are priced out. In public health, deadweight loss costs lives.

This is not a hypothetical scenario. U.S. Secretary of Health and Human Services Alex Azar has told Congress that the government will not intervene to guarantee affordability of COVID-19 vaccines in the U.S.

Secretary Azar has said the U.S. government wants the private sector to invest in vaccine development and manufacturing; if the U.S. sets prices, companies may not make that investment because the vaccines won’t be profitable. This view has been widely criticized. A commentator has called it “bad public health policy,” further pointing out that American taxpayers already fund a substantial amount of vaccine research and development in the U.S. Moreover, as legal scholars have pointed out, there are many regulatory perks and other incentives available exclusively to pharmaceutical companies.

If COVID-19 vaccines are not made available affordably to those who need them, the consequences will likely be disproportionately severe for poorer or otherwise vulnerable and marginalized populations. COVID-19 has already taken a higher toll on black and Latino populations. Without broad access to a vaccine, these populations will likely continue to suffer more than others, leading to unnecessary disease burden, continued economic problems and potential loss of life.

ADVERTISEMENT

What needs to be done

Nationalism is at odds with global public health principles. Yet, there are no provisions in international laws that prevent pre-purchase agreements like the ones described above. There is nothing inherently wrong with pre-purchase agreements of pharmaceutical products. Vaccines typically do not generate as much in sales as other medical products. If used correctly, pre-purchase agreements can even be an incentive for companies to manufacture vaccines that otherwise would not commercialized. Institutions like Gavi, an international nonprofit based in Geneva, use similar mechanisms to guarantee vaccines for developing countries.

But I see vaccine nationalism as a misuse of these agreements.

Contracts should not trump equitable access to global public health goods. I believe that developed countries should pledge to refrain from reserving vaccines for their populations during public health crises. The WHO’s Access to COVID-19 Tools Accelerator is a starting point for countries to test collaborative approaches during the current pandemic.

But more needs to be done. International institutions – including the WHO – should coordinate negotiations ahead of the next pandemic to produce a framework for equitable access to vaccines during public health crises. Equity entails both affordability of vaccines and access opportunities for populations across the world, irrespective of geography and geopolitics.

ADVERTISEMENT

Insofar as the U.S. can be considered a leader in the global health arena, I believe it should stop engaging in overly nationalistic behaviors. Failure to do so harms patient populations across the globe. Ultimately, it may harm its own citizens and residents, and perpetuate structural inequalities in our health care system.

[Get facts about coronavirus and the latest research. Sign up for The Conversation’s newsletter.]The Conversation

Ana Santos Rutschman, Assistant Professor of Law, Saint Louis University

This article is republished from The Conversation under a Creative Commons license. Read the original article.


Report typos and corrections to: [email protected].
READ COMMENTS - JOIN THE DISCUSSION
Continue Reading

Breaking Banner

‘People are dying’: Reporter backs Trump advisor Larry Kudlow into a corner on president’s gross negligence

Published

on

Tensions ran high at an outdoor press conference Friday when a reporter asked White House advisor Larry Kudlow, "Where is the President?" and he replied, "I don't understand."

The reporter said, "2,000 people a day are dying of COVID. Where is the President's leadership?"

CBS News White House correspondent Paula Reid reported from Washington, D.C. Friday and shared the tweet below. The responses flowed in from there.

https://twitter.com/PaulaReidCBS/status/1334889853276856322

https://twitter.com/CBSThisMorning/status/1334833494762147840?s=20

Continue Reading

Breaking Banner

‘On the spot’: Fauci confirms he immediately accepted Biden’s offer for chief medical adviser

Published

on

Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID) confirmed on Friday that he has accepted President-elect Joe Biden's offer to serve as chief medical adviser as the United States continues its fight against the coronavirus pandemic.

Fauci appeared on "The Today Show" where he told NBC host Savannah Guthrie that he accepted Biden's offer "on the spot." It has been reported that Fauci will continue his role as the director of the NIAID while leading the country's fight against COVID-19. At one point during the interview, Guthrie asked about the preliminary plan that will be put place during Biden's first 100 days in office.

Continue Reading
 

COVID-19

Top coronavirus aide warns US vaccination to take time

Published

on

The White House coordinator on the coronavirus response cautioned Thursday that vaccinations across the United States will take time, even for the most at risk including around one-third of Americans living with other serious conditions.

"That's probably the most important question right now. It will be a number of weeks, a number of months before the most vulnerable individuals in America" are vaccinated, Deborah Birx told reporters from AFP and AP at the United Nations.

"We have 100 million Americans with significant comorbidities. It is going to take time to get them immunized," she said after meeting Secretary-General Antonio Guterres, who led a largely virtual UN summit on the Covid-19 crisis.

Continue Reading